SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yu-hua Liu, Tao Wu, Ning Sun, Guang-li Wang, Jian-zhi Yuan, Yu-rong Dai, Xiao-hui Zhou, Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study, Journal of Huazhong University of Science and Technology [Medical Sciences], 2014, 34, 4, 542

    CrossRef

  2. 2
    Su-Ru Lin, Hung-Chih Yang, Yi-Ting Kuo, Chun-Jen Liu, Ta-Yu Yang, Ku-Chun Sung, You-Yu Lin, Hurng-Yi Wang, Chih-Chiang Wang, Yueh-Chi Shen, Fang-Yi Wu, Jia-Horng Kao, Ding-Shinn Chen, Pei-Jer Chen, The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo, Molecular Therapy—Nucleic Acids, 2014, 3, 8, e186

    CrossRef

  3. 3
    Mansour Sheikhan, S. Amir Ghoreishi, Antiviral therapy using a fuzzy controller optimized by modified evolutionary algorithms: a comparative study, Neural Computing and Applications, 2013, 23, 6, 1801

    CrossRef

  4. 4
    Timothy M. Block, Robert Gish, Haitao Guo, Anand Mehta, Andrea Cuconati, W. Thomas London, Ju-Tao Guo, Chronic hepatitis B: What should be the goal for new therapies?, Antiviral Research, 2013, 98, 1, 27

    CrossRef

  5. 5
    Stuart C. Gordon, Zahary Krastev, Andrzej Horban, Jörg Petersen, Jan Sperl, Phillip Dinh, Eduardo B. Martins, Leland J. Yee, John F. Flaherty, Kathryn M. Kitrinos, Vinod K. Rustgi, Patrick Marcellin, Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load, Hepatology, 2013, 58, 2
  6. 6
    A. M. Elaiw, M. A. Alghamdi, Shaban Aly, Hepatitis B Virus Dynamics: Modeling, Analysis, and Optimal Treatment Scheduling, Discrete Dynamics in Nature and Society, 2013, 2013, 1

    CrossRef

  7. 7
    Toshiaki Takayanagi, Modeling chronic hepatitis B or C virus infection during antiviral therapy using an analogy to enzyme kinetics: Long-term viral dynamics without rebound and oscillation, Computers in Biology and Medicine, 2013, 43, 12, 2021

    CrossRef

  8. 8
    Peter Karayiannis, Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis, Scientifica, 2012, 2012, 1

    CrossRef

  9. 9
    Marco Montagnani, Marina Giandinoto, Andrea Lisotti, Silvia Galli, Francesco Azzaroli, Federica Buonfiglioli, Laura Turco, Rita Aldini, Giuseppe Mazzella, High Dose Lamivudine in HBV-Related Cirrhotic Patients with Unsatisfactory Response After Adefovir Add-On, Digestive Diseases and Sciences, 2012, 57, 2, 561

    CrossRef

  10. 10
    Jianhua Pang, Jing-an Cui, Jing Hui, The importance of immune responses in a model of hepatitis B virus, Nonlinear Dynamics, 2012, 67, 1, 723

    CrossRef

  11. 11
    Redouane Qesmi, Susie ElSaadany, Jane Marie Heffernan, Jianhong Wu, A Hepatitis B and C Virus Model with Age since Infection that Exhibits Backward Bifurcation, SIAM Journal on Applied Mathematics, 2011, 71, 4, 1509

    CrossRef

  12. 12
    Jun Nakabayashi, Akira Sasaki, A mathematical model of the intracellular replication and within host evolution of hepatitis type B virus: Understanding the long time course of chronic hepatitis, Journal of Theoretical Biology, 2011, 269, 1, 318

    CrossRef

  13. 13
    Sylvain Goutelle, Laurent Bourguignon, Roger W. Jelliffe, John E. Conte, Pascal Maire, Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin, Journal of Theoretical Biology, 2011, 282, 1, 80

    CrossRef

  14. 14
    Xiangdong David Ren, Hui Nie, Ju-Tao Guo, HBV Drug Resistance Development, Testing, and Prevention, Current Hepatitis Reports, 2010, 9, 4, 223

    CrossRef

  15. 15
    Redouane Qesmi, Jun Wu, Jianhong Wu, Jane M. Heffernan, Influence of backward bifurcation in a model of hepatitis B and C viruses, Mathematical Biosciences, 2010, 224, 2, 118

    CrossRef

  16. 16
    Chanunta Hongthanakorn, Anna S.F. Lok, New Pharmacologic Therapies in Chronic Hepatitis B, Gastroenterology Clinics of North America, 2010, 39, 3, 659

    CrossRef

  17. 17
    Avidan U. Neumann, Sandra Phillips, Idit Levine, Samreen Ijaz, Harel Dahari, Rachel Eren, Shlomo Dagan, Nikolai V. Naoumov, Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells, Hepatology, 2010, 52, 3
  18. 18
    L. Rong, H. Dahari, R. M. Ribeiro, A. S. Perelson, Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus, Science Translational Medicine, 2010, 2, 30, 30ra32

    CrossRef

  19. 19
    Jin Yang, Ting Cai, Guo-Qiang Lou, Anti-hepatitis B virus treatment guided by long-term virus kinetics stepwise tracing, Journal of Gastroenterology and Hepatology, 2009, 24, 6
  20. 20
    Nancy Leung, Cheng-Yuan Peng, Hie-Won Hann, Jose Sollano, Judy Lao-Tan, Chao-Wei Hsu, Laurentius Lesmana, Man-Fung Yuen, Lennox Jeffers, Morris Sherman, Albert Min, Kimberly Mencarini, Ulysses Diva, Anne Cross, Richard Wilber, Juan Lopez-Talavera, Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir, Hepatology, 2009, 49, 1
  21. 21
    Harel Dahari, Emi Shudo, Ruy M. Ribeiro, Alan S. Perelson, Modeling complex decay profiles of hepatitis B virus during antiviral therapy, Hepatology, 2009, 49, 1
  22. 22
    Maura Dandri, Jörg Petersen, John M. Murray, Reply:, Hepatology, 2009, 49, 5
  23. 23
    Jinjun Chen, Zhanhui Wang, Yabing Guo, Jie Peng, Jian Sun, Choudhary Shoaib Ahmed, Yuanping Zhou, Jinlin Hou, Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-α-2a, Antiviral Research, 2009, 81, 1, 88

    CrossRef

  24. 24
    Tin Nguyen, Paul Desmond, Stephen Locarnini, The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B, Hepatology International, 2009, 3, S1, 5

    CrossRef

  25. 25
    Sharon R. Lewin, Ruy M. Ribeiro, Anchalee Avihingsanon, Scott Bowden, Gail Matthews, Pip Marks, Stephen A. Locarnini, Kiat Ruxrungtham, Alan S. Perelson, Gregory J. Dore, Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1–hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy, Hepatology, 2009, 49, 4
  26. 26
    E. Shudo, R. M. Ribeiro, A. S. Perelson, Modelling hepatitis C virus kinetics during treatment with pegylated interferon α-2b: errors in the estimation of viral kinetic parameters, Journal of Viral Hepatitis, 2008, 15, 5
  27. 27
    Vana Sypsa, Angelos Hatzakis, Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials, Statistics in Medicine, 2008, 27, 30
  28. 28
    Maurizia Rossana Brunetto, Piero Colombatto, Ferruccio Bonino, Personalized therapy in chronic viral hepatitis, Molecular Aspects of Medicine, 2008, 29, 1-2, 103

    CrossRef

  29. 29
    V. Soriano, A. S. Perelson, F. Zoulim, Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?, Journal of Antimicrobial Chemotherapy, 2008, 62, 1, 1

    CrossRef

  30. 30
    I-Chin Wu, Nan-Haw Chow, Pin-Nan Cheng, Wen-Chun Liu, Kung-Chia Young, Wei-Lun Chang, Chi-Yi Chen, Kuo-Chih Tseng, Ting-Tsung Chang, Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B, Journal of Medical Virology, 2007, 79, 6
  31. 31
    Robert G. Gish, Improving outcomes for patients with chronic hepatitis B, Hepatology Research, 2007, 37,
  32. 32
    Stanca M. Ciupe, Ruy M. Ribeiro, Patrick W. Nelson, Alan S. Perelson, Modeling the mechanisms of acute hepatitis B virus infection, Journal of Theoretical Biology, 2007, 247, 1, 23

    CrossRef

  33. 33
    Maurizia Rossana Brunetto, Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance, Journal of Hepatology, 2007, 46, 5, 756

    CrossRef

  34. 34
    S. M. Ciupe, R. M. Ribeiro, P. W. Nelson, G. Dusheiko, A. S. Perelson, The role of cells refractory to productive infection in acute hepatitis B viral dynamics, Proceedings of the National Academy of Sciences, 2007, 104, 12, 5050

    CrossRef

  35. 35
    Xuan Xiao, Shi-Huang Shao, Kuo-Chen Chou, A probability cellular automaton model for hepatitis B viral infections, Biochemical and Biophysical Research Communications, 2006, 342, 2, 605

    CrossRef

  36. 36
    Gail V Matthews, Angeline Bartholomeusz, Stephen Locarnini, Anna Ayres, Joe Sasaduesz, Eric Seaberg, David A Cooper, Sharon Lewin, Gregory J Dore, Chloe L Thio, Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy, AIDS, 2006, 20, 6, 863

    CrossRef

  37. 37
    Robert G. Gish, Stephen A. Locarnini, Chronic Hepatitis B: Current Testing Strategies, Clinical Gastroenterology and Hepatology, 2006, 4, 6, 666

    CrossRef

  38. 38
    F. Blaine Hollinger, Daryl T.-Y. Lau, Hepatitis B: The Pathway to Recovery Through Treatment, Gastroenterology Clinics of North America, 2006, 35, 4, 895

    CrossRef

  39. 39
    F. Blaine Hollinger, Daryl T.-Y. Lau, Hepatitis B: The Pathway to Recovery Through Treatment, Gastroenterology Clinics of North America, 2006, 35, 2, 425

    CrossRef

  40. 40
    Kimberly A. Powers, Ruy M. Ribeiro, Keyur Patel, Stephen Pianko, Lisa Nyberg, Paul Pockros, Andrew J. Conrad, John McHutchison, Alan S. Perelson, Kinetics of hepatitis C virus reinfection after liver transplantation, Liver Transplantation, 2006, 12, 2
  41. 41
    Martijn J. ter Borg, Monika van Zonneveld, Stefan Zeuzem, Hakan Senturk, Ulus S. Akarca, Christopher Simon, Bettina E. Hansen, Bart L. Haagmans, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen, Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response, Hepatology, 2006, 44, 3
  42. 42
    John M. Murray, Robert H. Purcell, Stefan F. Wieland, The half-life of hepatitis B virions, Hepatology, 2006, 44, 5
  43. 43
    T.E.M.S. de Vries-Sluijs, A.A. van der Eijk, B.E. Hansen, A.D.M.E. Osterhaus, R.A. de Man, M.E. van der Ende, Wild type and YMDD variant of hepatitis B virus: No difference in viral kinetics on lamivudine/tenofovir therapy in HIV–HBV co-infected patients, Journal of Clinical Virology, 2006, 36, 1, 60

    CrossRef

  44. 44
    Anastasia Rivkin, A review of entecavir in the treatment of chronic hepatitis B infection, Current Medical Research and Opinion, 2005, 21, 11, 1845

    CrossRef

  45. 45
    Vassiliki-Anastasia Sypsa, Konstantinos Mimidis, Nicholas C. Tassopoulos, Dimitrios Chrysagis, Themistoklis Vassiliadis, Antonios Moulakakis, Maria Raptopoulou, Caterina Haida, Angelos Hatzakis, A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative, Hepatology, 2005, 42, 1
  46. 46
    David Mutimer, Adefovir-lamivudine combination therapy and hepatitis B viral kinetics, Journal of Hepatology, 2005, 43, 2, 200

    CrossRef

  47. 47
    Avidan U. Neumann, Hepatitis B viral kinetics: A dynamic puzzle still to be resolved, Hepatology, 2005, 42, 2
  48. 48
    Karine Lacombe, Joël Gozlan, Pierre-Yves Boelle, Lawrence Serfaty, Fabien Zoulim, Alain-Jacques Valleron, Pierre-Marie Girard, Long-term hepatitis B virus dynamics in HIV–hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate, AIDS, 2005, 19, 9, 907

    CrossRef

  49. 49
    Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Molecular virology and drug resistance in antiviral therapy of chronic hepatitis B, Current Hepatitis Reports, 2005, 4, 1, 27

    CrossRef

  50. 50
    Fabien Zoulim, New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA, Journal of Hepatology, 2005, 42, 3, 302

    CrossRef

  51. 51
    David Durantel, Marie-Noelle Brunelle, Edwige Gros, Sandra Carrouée-Durantel, Christian Pichoud, Stephanie Villet, Christian Trepo, Fabien Zoulim, Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing, Journal of Clinical Virology, 2005, 34, S34

    CrossRef

  52. 52
    Samuel Litwin, Eugene Toll, Allison R. Jilbert, William S. Mason, The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: Theoretical considerations, Journal of Clinical Virology, 2005, 34, S96

    CrossRef

  53. 53
    A. A. Eijk, B. E. Hansen, H. G. M. Niesters, H. L. A. Janssen, M. Ende, S. W. Schalm, R. A. Man, Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants, Journal of Viral Hepatitis, 2005, 12, 4
  54. 54
    Ulrike Mihm, Barbara Christine Gärtner, Dominik Faust, Wolf Peter Hofmann, Christoph Sarrazin, Stefan Zeuzem, Eva Herrmann, Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir–lamivudine combination therapy, Journal of Hepatology, 2005, 43, 2, 217

    CrossRef

  55. 55
    Ching-Lung Lai, Seng Gee Lim, Nathaniel A. Brown, Xiao-Jian Zhou, Deborah M. Lloyd, Yin-Mei Lee, Man-Fung Yuen, George C. Chao, Maureen W. Myers, A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection, Hepatology, 2004, 40, 3
  56. 56
    Daryl T.-Y. Lau, Fernando E. Membreno, Antiviral therapy for treatment-naı̈ve hepatitis B virus patients, Gastroenterology Clinics of North America, 2004, 33, 3, 581

    CrossRef

  57. 57
    B. Werle, K. Cinquin, P. Marcellin, S. Pol, M. Maynard, C. Trépo, F. Zoulim, Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy, Journal of Viral Hepatitis, 2004, 11, 1
  58. 58
    C. C. Wang, S. Holte, M.-L. Huang, S. L. Sacks, R. Engelberg, J. Ferrenberg, M. Shuhart, L. Corey, Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily, Journal of Viral Hepatitis, 2004, 11, 5
  59. 59
    Susanne Beckebaum, Vito R. Cicinnati, Guido Gerken, Christoph Erich Broelsch, Management of chronic hepatitis B in the liver transplant setting, Transplantation Reviews, 2004, 18, 4, 171

    CrossRef

  60. 60
    SCOTT BOWDEN, New directions in molecular diagnostics for hepatitis B: serum and tissue-based diagnostics, Journal of Gastroenterology and Hepatology, 2004, 19,
  61. 61
    Roula B. Qaqish, Keri A. Mattes, David J. Ritchie, Adefovir dipivoxil: A new antiviral agent for the treatment of hepatitis B virus infection, Clinical Therapeutics, 2003, 25, 12, 3084

    CrossRef

  62. 62
    Franck Le Guerhier, Alexandre Thermet, Sylvianne Guerret, Michèle Chevallier, Catherine Jamard, Craig S. Gibbs, Christian Trépo, Lucyna Cova, Fabien Zoulim, Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model, Journal of Hepatology, 2003, 38, 3, 328

    CrossRef

  63. 63
    Chi-Tai Fang, Pei-Jer Chen, Mao-Yuan Chen, Chien-Ching Hung, Shan-Chwen Chang, An-Lung Chang, Ding-Shinn Chen, Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection, Journal of Hepatology, 2003, 39, 6, 1028

    CrossRef

  64. 64
    Susanne Beckebaum, Massimo Malagó, Olaf Dirsch, Vito R Cicinnati, Martin Trippler, Pietro Lampertico, Nicole Lama, Ulrich Treichel, Guido Gerken, Christoph E Broelsch, Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation, Clinical Transplantation, 2003, 17, 6
  65. 65
    Stephen Locarnini, Hepatitis B viral resistance: mechanisms and diagnosis, Journal of Hepatology, 2003, 39, 124

    CrossRef

  66. 66
    Jean-Michel Pawlotsky, Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics, Journal of Hepatology, 2003, 39, 31

    CrossRef

  67. 67
    Robert P. Perrillo, Hepatitis B: Treatment strategies for currently available drugs, Current Hepatitis Reports, 2003, 2, 2, 63

    CrossRef

  68. 68
    Vladimir P. Chulanov, German A. Shipulin, Stephan Schaefer, Wolfram H. Gerlich, Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses, Journal of Medical Virology, 2003, 69, 3
  69. 69
    Eugene R Schiff, Jules L Dienstag, Selim Karayalcin, Ian S Grimm, Robert P Perrillo, Petr Husa, R.A de Man, Zachary Goodman, Lynn D Condreay, Lynn M Crowther, Mary A Woessner, Penny J McPhillips, Nathaniel A Brown, Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders, Journal of Hepatology, 2003, 38, 6, 818

    CrossRef

  70. 70
    Thomas J Layden, Jennifer E Layden, Ruy M Ribeiro, Alan S Perelson, Mathematical modeling of viral kinetics:, Clinics in Liver Disease, 2003, 7, 1, 163

    CrossRef

  71. 71
    S. Hagmann, M. Chung, G. Rochford, M. Jani, C. Trinh-Shevrin, Y. Sitnitskaya, A. U. Neumann, H. Pollack, Response to Lamivudine Treatment in Children with Chronic Hepatitis B Virus Infection, Clinical Infectious Diseases, 2003, 37, 11, 1434

    CrossRef

  72. 72
    Ruth Chin, Stephen Locarnini, Treatment of chronic hepatitis B: current challenges and future directions, Reviews in Medical Virology, 2003, 13, 4
  73. 73
    Angeline Bartholomeusz, Phillip Furman, Stephen Locarnini, Frontiers in Viral Hepatitis, 2003,

    CrossRef

  74. 74
    Justin G Julander, Robert W Sidwell, John D Morrey, Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus, Antiviral Research, 2002, 55, 1, 27

    CrossRef

  75. 75
    Tim Shaw, Scott Bowden, Stephen Locarnini, Chemotherapy for hepatitis B: New treatment options necessitate reappraisal of traditional endpoints, Gastroenterology, 2002, 123, 6, 2135

    CrossRef

  76. 76
    Ruy M. Ribeiro, Arthur Lo, Alan S. Perelson, Dynamics of hepatitis B virus infection, Microbes and Infection, 2002, 4, 8, 829

    CrossRef

  77. 77
    Ching–Lung Lai, Mohamed Rosmawati, Judy Lao, Hans Van Vlierberghe, Frank H. Anderson, Neal Thomas, Deborah Dehertogh, Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection, Gastroenterology, 2002, 123, 6, 1831

    CrossRef

  78. 78
    William E Delaney IV, Angeline Bartholomeusz, Stephen A Locarnini, Evolving therapies for the treatment of chronic hepatitis B virus infection, Expert Opinion on Investigational Drugs, 2002, 11, 2, 169

    CrossRef

  79. 79
    Sharon Lewin, Tomos Walters, Stephen Locarnini, Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies, Antiviral Research, 2002, 55, 3, 381

    CrossRef

  80. 80
    Ruy M Ribeiro, Alan S Perelson, Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase, Journal of Hepatology, 2002, 37, 2, 277

    CrossRef

  81. 81
    Deenan Pillay, HIV viral load: the myth of the undetectable?, Reviews in Medical Virology, 2002, 12, 6
  82. 82
    Robert P. Perrillo, How will we use the new antiviral agents for hepatitis B?, Current Gastroenterology Reports, 2002, 4, 1, 63

    CrossRef

  83. 83
    CHUTIMA PRAMOOLSINSUP, Management of viral hepatitis B, Journal of Gastroenterology and Hepatology, 2002, 17,
  84. 84
    Patrick W. Nelson, Alan S. Perelson, Mathematical analysis of delay differential equation models of HIV-1 infection, Mathematical Biosciences, 2002, 179, 1, 73

    CrossRef

  85. 85
    Alan S. Perelson, MODELLING VIRAL AND IMMUNE SYSTEM DYNAMICS, Nature Reviews Immunology, 2002, 2, 1, 28

    CrossRef

  86. 86
    Leonieke M.M. Wolters, Bettina E. Hansen, Hubert G.M. Niesters, Rachel S. Levi-Drummer, Avidan U. Neumann, Solko W. Schalm, Robert A. de Man, The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine, Journal of Hepatology, 2002, 37, 2, 253

    CrossRef

  87. 87
    Leonieke M.M Wolters, Bettina E Hansen, Hubert G.M Niesters, Deborah DeHertogh, Robert A de Man, Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B, Journal of Hepatology, 2002, 37, 1, 137

    CrossRef

  88. 88
    LMM Wolters, BE Hansen, HGM Niesters, S Zeuzem, SW Schalm, Man. RA de, Lonieke M. M. Wolters, Bettina E. Hansen, Hubert G. M. Niesters, Stefan Zeuzem, Solko W. Schalm, Robert A. De Man, Viral dynamics in chronic hepatitis B patients during lamivudine therapy, Liver, 2002, 22, 2
  89. 89
    Leonieke M. M. Wolters, Bettina E. Hansen, Hubert G. M. Niesters, Robert A. de Man, Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine–famciclovir or lamivudine–ganciclovir, European Journal of Gastroenterology & Hepatology, 2002, 14, 9, 1007

    CrossRef

  90. 90
    Mark V Galan, Stuart C Gordon, Douglas Boyce, Current pharmacotherapy for hepatitis B infection, Expert Opinion on Pharmacotherapy, 2001, 2, 8, 1289

    CrossRef

  91. 91
    Béatrice Seignères, Stéphanie Aguesse-Germon, Christian Pichoud, Isabelle Vuillermoz, Catherine Jamard, Christian Trépo, Fabien Zoulim, Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo, Journal of Hepatology, 2001, 34, 1, 114

    CrossRef

  92. 92
    Jennifer E. Layden, Thomas J. Layden, How can mathematics help us understand HCV?, Gastroenterology, 2001, 120, 6, 1546

    CrossRef

  93. 93
    S. A. Whalley, J. M. Murray, D. Brown, G. J.M. Webster, V. C. Emery, G. M. Dusheiko, A. S. Perelson, Kinetics of Acute Hepatitis B Virus Infection in Humans, Journal of Experimental Medicine, 2001, 193, 7, 847

    CrossRef

  94. 94
    Karl P Fischer, Klaus S Gutfreund, D.Lorne Tyrrell, Lamivudine resistance in hepatitis B: mechanisms and clinical implications, Drug Resistance Updates, 2001, 4, 2, 118

    CrossRef

  95. 95
    B Werle, F Zoulim, Nouveaux traitements de l'hépatite B et techniques d'étude de la résistance virale, Immuno-analyse & Biologie Spécialisée, 2001, 16, 3, 158

    CrossRef

  96. 96
    Leonieke M. M. Wolters, Hubert G. M. Niesters, Robert A. de Man, Nucleoside analogues for chronic hepatitis B, European Journal of Gastroenterology & Hepatology, 2001, 13, 12, 1499

    CrossRef

  97. 97
    Antonín Holý, Ivan Votruba, Eva Tloušťová, Milena Masojídková, Synthesis and Cytostatic Activity of N-[2-(Phosphonomethoxy)alkyl] Derivatives of N6-Substituted Adenines, 2,6-Diaminopurines and Related Compounds, Collection of Czechoslovak Chemical Communications, 2001, 66, 10, 1545

    CrossRef

  98. 98
    Suzane Kioko Ono, Naoya Kato, Yasushi Shiratori, Jun Kato, Tadashi Goto, Raymond F. Schinazi, Flair José Carrilho, Masao Omata, The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance, Journal of Clinical Investigation, 2001, 107, 4, 449

    CrossRef

  99. 99
    Man-Fung Yuen, Ching-Lung Lai, Treatment of chronic hepatitis B, The Lancet Infectious Diseases, 2001, 1, 4, 232

    CrossRef

  100. 100
    Zhensheng Zhang, Nobuyuki Torii, Zongyi Hu, James Jacob, T. Jake Liang, X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo, Journal of Clinical Investigation, 2001, 108, 10, 1523

    CrossRef

  101. 101
    Zhensheng Zhang, Nobuyuki Torii, Zongyi Hu, James Jacob, T. Jake Liang, X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo, Journal of Clinical Investigation, 2001, 108, 10, 1523

    CrossRef

  102. 102
    Joseph Torresi, Stephen Locarnini, Antiviral chemotherapy for the treatment of hepatitis b virus infections, Gastroenterology, 2000, 118, 2, S83

    CrossRef

  103. 103
    Tim Shaw, Stephen Locarnini, Combination Chemotherapy for Hepatitis B Virus, Drugs, 2000, 60, 3, 517

    CrossRef

  104. 104
    Deenan Pillay, Patricia A. Cane, Daina Ratcliffe, Mark Atkins, David Cooper, Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study, AIDS, 2000, 14, 9, 1111

    CrossRef

  105. 105
    Anna Suk-Fong Lok, Hepatitis B infection: Pathogenesis and management, Journal of Hepatology, 2000, 32, 89

    CrossRef

  106. 106
    Bernd Kronenberger, Brigitte Rüster, Jung-Hun Lee, Christoph Sarrazin, W.Kurt Roth, Günter Herrmann, Stefan Zeuzem, Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels, Journal of Hepatology, 2000, 33, 4, 640

    CrossRef

  107. 107
    Z Zı́dek, D Franková, A Holý, Macrophage activation by antiviral acyclic nucleoside phosphonates in dependence on priming immune stimuli, International Journal of Immunopharmacology, 2000, 22, 12, 1121

    CrossRef

  108. 108
    Fabien Zoulim, Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies, Antiviral Research, 1999, 44, 1, 1

    CrossRef

  109. 109
    Ramachandra S. Hosmane, Antiviral Agents, Kirk-Othmer Encyclopedia of Chemical Technology,